More than a dozen peptides will likely be removed from a federal prohibition that bars compounding pharmacies from manufacturing the substances, according to a recent report. The U.S. Food and Drug Administration (FDA) is preparing to lift restrictions on these compounds, which had been banned due to safety and efficacy concerns. Among the peptides set for delisting is semaglutide, a compound widely used in drugs like Ozempic and Wegovy for diabetes and weight management. The move follows recommendations from the Department of Health and Human Services (HHS) and a review process that evaluates whether these substances can be safely produced by licensed pharmacies. If finalized, the change would allow compounding pharmacies to resume production under specific regulatory conditions, potentially increasing access to customized formulations for patients with unique medical needs. The FDA has not yet announced a final decision, but industry insiders expect the update to be formalized in the coming weeks. Robert F. Kennedy Jr., a vocal critic of pharmaceutical regulations, has previously endorsed certain peptide therapies and criticized the ban, calling it "a barrier to medical freedom."
When Robert F. Kennedy Jr. frames the peptide ban as a restriction on medical freedom, it reflects a broader push to loosen oversight on personalized treatments—regardless of proven safety. The FDA's potential reversal signals a shift toward accommodating demand for compounded drugs, even as questions remain about quality control outside mass production. For Nigerian healthcare innovators eyeing telemedicine or personalized treatments, this highlights both opportunities and risks in adopting similar models without robust local regulation. The global conversation on drug compounding may influence how startups in Nigeria approach regulatory compliance in digital health.
